The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-062: phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck; Merck Serono; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Yung-Jue Bang
Consulting or Advisory Role - Merck Sharp & Dohme
 
Charles S. Fuchs
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Entrinsic Health; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; Lilly; Macrogenics; MedImmune; Merck; Pfizer; Sanofi; Takeda
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Uma Kher
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Baohoang Lam
Employment - Merck Sharp & Dohme
 
Minori Koshiji
Employment - Merck Sharp & Dohme
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)